Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOAR: Fostamatinib in warm antibody autoimmune hemolytic anemia
NCT02612558Phase 2Completed
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Jul 2016
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of fostamatinib in warm antibody autoimmune hemolytic anemia (WAIHA), sponsored by Rigel Pharmaceuticals, Inc.. Started Jul 2016; status: completed.
02
Drugs
fostamatinib
03
Conditions
warm antibody autoimmune hemolytic anemia (WAIHA)
Beyond the preview
Go deeper on NCT02612558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02612558.